MA53743A - Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 - Google Patents
Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3Info
- Publication number
- MA53743A MA53743A MA053743A MA53743A MA53743A MA 53743 A MA53743 A MA 53743A MA 053743 A MA053743 A MA 053743A MA 53743 A MA53743 A MA 53743A MA 53743 A MA53743 A MA 53743A
- Authority
- MA
- Morocco
- Prior art keywords
- aging
- compositions
- methods
- disorders related
- treating disorders
- Prior art date
Links
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 title 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 title 1
- 230000032683 aging Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53743A true MA53743A (fr) | 2022-01-05 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053743A MA53743A (fr) | 2018-09-26 | 2019-09-25 | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (https=) |
| JP (2) | JP7528065B2 (https=) |
| KR (1) | KR20210065950A (https=) |
| CN (1) | CN112789044A (https=) |
| AU (1) | AU2019346456A1 (https=) |
| BR (1) | BR112021004938A2 (https=) |
| CL (1) | CL2021000724A1 (https=) |
| CO (1) | CO2021003713A2 (https=) |
| EA (1) | EA202190463A1 (https=) |
| IL (1) | IL281578A (https=) |
| MA (1) | MA53743A (https=) |
| MX (1) | MX2021002967A (https=) |
| SG (1) | SG11202102105VA (https=) |
| TW (1) | TW202027752A (https=) |
| WO (1) | WO2020069008A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113689A1 (en) | 2018-09-25 | 2020-04-02 | Antabio Sas | Indane derivatives for use in the treatment of bacterial infection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| MX2011011080A (es) | 2009-04-22 | 2012-02-23 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida. |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| MY199462A (en) * | 2017-04-05 | 2023-10-30 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| CN110636844A (zh) * | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
-
2019
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko not_active Withdrawn
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en not_active Ceased
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
-
2024
- 2024-07-24 JP JP2024118649A patent/JP2024153742A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004938A2 (pt) | 2021-06-01 |
| JP7528065B2 (ja) | 2024-08-05 |
| TW202027752A (zh) | 2020-08-01 |
| CO2021003713A2 (es) | 2021-04-08 |
| AU2019346456A1 (en) | 2021-04-15 |
| KR20210065950A (ko) | 2021-06-04 |
| JP2024153742A (ja) | 2024-10-29 |
| EP3856195A4 (en) | 2022-06-22 |
| CN112789044A (zh) | 2021-05-11 |
| EA202190463A1 (ru) | 2021-06-29 |
| CL2021000724A1 (es) | 2021-10-15 |
| SG11202102105VA (en) | 2021-04-29 |
| MX2021002967A (es) | 2021-08-11 |
| IL281578A (en) | 2021-05-31 |
| JP2022502441A (ja) | 2022-01-11 |
| CA3111433A1 (en) | 2020-04-02 |
| EP3856195A1 (en) | 2021-08-04 |
| WO2020069008A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2352517A4 (en) | METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES | |
| EP3917539A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS | |
| EP3793566A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING SPLICEOPATHY AND TREATMENT OF RNA DOMINANCE DISORDERS | |
| EP3973047A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASES | |
| MA54880A (fr) | Compositions et procédés de traitement de troubles neurocognitifs | |
| EP3813793A4 (en) | COMPOSITION FOR THE TREATMENT OF OCULAR HYPEREMIA AND METHODS FOR TREATMENT OF OCULAR HYPEREMIA THEREFORE | |
| EP3490366A4 (en) | METHOD AND COMPOSITIONS FOR GENE EXPRESSION IN PLANTS | |
| EP3969597A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATPASE-MEDIATED DISEASES | |
| EP3826468A4 (en) | COMPOSITIONS AND RELATED PROCEDURES FOR AGRICULTURE | |
| EP3368080A4 (en) | TREATMENT OF DISEASES OF THE NERVOUS SYSTEM USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | |
| EP3793562A4 (en) | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | |
| MA53234A (fr) | Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques | |
| EP4045046A4 (en) | Methods and compositions for treating iron disorders | |
| EP3701048A4 (en) | PROCEDURES AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF INTRAOCULAR DISEASES AND DISORDERS | |
| EP2453743A4 (en) | N-ACETYL-CYSTEIN COMPOSITIONS AND METHODS FOR IMPROVED THERAPEUTIC EFFECT OF ACETAMINOPHES | |
| EP4058062A4 (en) | Compositions and methods for immunotherapy | |
| EP3737367A4 (en) | METHOD OF TREATMENT OF SOLID TUMORS WITH CCR2 ANTAGONISTS | |
| EP3969041A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION | |
| EP4110461A4 (en) | COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH | |
| EP3801577A4 (en) | METHOD AND COMPOSITIONS USING TANKYRASE INHIBITOR FOR GENERATING INSULIN-PRODUCING CELLS | |
| EP3661492A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF NERVOUS DISORDERS | |
| MA53743A (fr) | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 | |
| EP3857224A4 (en) | PROCEDURES AND COMPOSITIONS FOR THE REMOVAL OF BIOTIN INTERFERENCE FROM ASSAYS WITH MOLECULAR TRAPS | |
| EP4031567A4 (en) | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION | |
| EP3946380A4 (en) | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY |